Please login to the form below

Not currently logged in

Pfizer names new emerging markets chief

Pfizer has appointed David Simmons to serve as its new head of emerging markets, succeeding Jean-Michel Halfon
Pfizer has appointed David Simmons to serve as its new head of emerging markets, succeeding Jean-Michel Halfon, according to a report from Bloomberg attributed to a company spokesperson. Halfon's retirement, which is effective in the first quarter of 2011, was announced internally a week ago but was not made public at the time. 

Simmons will continue as president and general manager of the Established Products Business Unit, a role in which he oversees drugs with expired patents as well as generics made by Pfizer's Greenstone unit, and will add Halfon's emerging markets duties to his existing ones. 

The Established Products Business Unit was created about two years ago under Simmons' leadership. Simmons has been working for Pfizer for 12 years in regions including the UK, Greece, Canada and the US.  He serves as the executive sponsor of the Pfizer African American Leadership Network and as a member of the US-India Business Council. Earlier in his career, he was an executive in the steel industry.

Halfon has been with Pfizer since 1997, serving in roles including head of Pfizer's Canada operations before taking over the emerging markets business. 

Simmons' new role comes amidst much larger management changes for Pfizer, which announced this week that Jeffrey Kindler was stepping down as CEO after four and a half years and would be replaced by Ian Reed, who has been in charge of worldwide pharma operations at the company since 2006.

9th December 2010


Featured jobs

Subscribe to our email news alerts


Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...